Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report

20231 citationsJournal Articlegold Open Access

Authors

Dominik Lehrieder · Universitätsklinikum Würzburg

Nikolaos Zapantis · Universitätsklinikum Würzburg

Mirko Pham · Universitätsklinikum Würzburg

Michael K. Schuhmann · Universitätsklinikum Würzburg

Axel Haarmann · Universitätsklinikum Würzburg

Abstract

Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.

Topics & Keywords

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Systemic Lupus Erythematosus Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Neurology

Volume 14, pp. 1297341-1297341

DOI: 10.3389/fneur.2023.1297341

Field-Weighted Citation Impact: 0.26